RHOA and neoplasm: Our laboratory had previously reported that vGPCR targeted the HO-1 promoter through the Gα12/13-RhoA proteins and that the development of these tumors was mediated by HO-1; we have also demonstrated that pharmacological inhibition or decreased HO-1 expression produced a decrease in tumor size (40).